Budget Impact Analysis of Dasatinib as a Second-Line Therapy in Patients with Chronic Myelogenous Leukemia (Cml) in the Russian Federation
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1085
https://www.valueinhealthjournal.com/article/S1098-3015(15)03161-7/fulltext
Title :
Budget Impact Analysis of Dasatinib as a Second-Line Therapy in Patients with Chronic Myelogenous Leukemia (Cml) in the Russian Federation
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03161-7&doi=10.1016/j.jval.2015.09.1085
First page :
A441
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
585